SAN DIEGO, July 29, 2021 /PRNewswire/ — Robbins Geller Rudman & Dowd LLP announces that a class action lawsuit has been filed on behalf of purchasers of Frequency Therapeutics, Inc. (NASDAQ: FREQ) popular inventory in between November 16, 2020 and March 22, 2021, inclusive (the “Course Interval”). The Frequency Therapeutics course action lawsuit rates Frequency Therapeutics and specific of its executives with violations of the Securities Exchange Act of 1934. The Frequency Therapeutics course motion lawsuit (Evans v. Frequency Therapeutics, Inc., No. 21-cv-10933) was submitted in the District of Massachusetts and is assigned to Judge William G. Younger. A identical lawsuit (Hingston v. Frequency Therapeutics, Inc., No. 21-cv-11040) is also pending in the District of Massachusetts.
If you experienced sizeable losses and wish to serve as guide plaintiff of the Frequency Therapeutics class motion lawsuit, make sure you offer your facts by clicking listed here. You can also get hold of legal professional J.C. Sanchez of Robbins Geller by contacting 800/449-4900 or by means of e-mail at [email protected]. Direct plaintiff motions for the Frequency Therapeutics class motion lawsuit have to be submitted with the courtroom no later than August 2, 2021.
Scenario ALLEGATIONS: The Frequency Therapeutics course action lawsuit alleges that, shortly immediately after launching the Stage Forex-322 2a trial, Frequency Therapeutics and its Chief Government Officer, defendant David L. Lucchino, uncovered that the Phase 2a demo final results disclosed no discernable variation amongst Fx-322 and the placebo. The Frequency Therapeutics course motion lawsuit additional alleges that, although Frequency Therapeutics’ stock value remained artificially inflated, defendant Lucchino offered in excess of 350,000 Frequency Therapeutics shares, pocketing above $10.5 million.
On March 23, 2021, Frequency Therapeutics disclosed deeply disappointing interim Phase 2a effects, revealing that subjects with gentle to reasonable serious sensorineural hearing reduction did not demonstrate advancements in hearing actions vs . placebo. On this news, Frequency Therapeutics’ inventory price fell by approximately 78%, harmful traders.
THE Direct PLAINTIFF Method: The Private Securities Litigation Reform Act of 1995 permits any investor who ordered Frequency Therapeutics common stock all through the Class Period of time to request appointment as lead plaintiff in the Frequency Therapeutics course motion lawsuit. A direct plaintiff is typically the movant with the greatest financial fascination in the aid sought by the putative class who is also standard and enough of the putative class. A guide plaintiff functions on behalf of all other course members in directing the Frequency Therapeutics class action lawsuit. The guide plaintiff can pick a regulation firm of its alternative to litigate the Frequency Therapeutics course action lawsuit. An investor’s skill to share in any prospective upcoming recovery of the Frequency Therapeutics class motion lawsuit is not dependent upon serving as direct plaintiff.
ABOUT ROBBINS GELLER RUDMAN & DOWD LLP: With 200 attorneys in 9 workplaces nationwide, Robbins Geller Rudman & Dowd LLP is the premier U.S. legislation firm representing investors in securities course actions. Robbins Geller attorneys have attained a lot of of the most significant shareholder recoveries in background, including the biggest securities course motion restoration ever – $7.2 billion – in In re Enron Corp. Sec. Litig. The 2020 ISS Securities Class Action Products and services Leading 50 Report rated Robbins Geller 1st for recovering $1.6 billion for buyers final yr, much more than double the total recovered by any other securities plaintiffs’ organization. Remember to go to https://www.rgrdlaw.com/organization.html for extra data.
Legal professional promoting.
Past final results do not assurance future results.
Providers could be executed by lawyers in any of our offices.
Contact:
Robbins Geller Rudman & Dowd LLP
655 W. Broadway, San Diego, CA 92101
J.C. Sanchez, 800-449-4900
[email protected]
View original content:https://www.prnewswire.com/information-releases/monday-deadline-investors-with-sizeable-losses-have-prospect-to-guide-the-frequency-therapeutics-inc-class-action-lawsuit—freq-301343704.html
Supply Robbins Geller Rudman & Dowd LLP
